Section Arrow
SNGX.NASDAQ
- Soligenix Inc.
Quotes are at least 15-min delayed:2024/10/31 18:49 EDT
Last
 3.67
-0.06 (-1.61%)
Day High 
3.82 
Prev. Close
3.73 
1-M High
4.87 
Volume 
41.25K 
Bid
3.63
Ask
3.67
Day Low
3.5999 
Open
3.77 
1-M Low
3.5 
Market Cap 
8.51M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.75 
20-SMA 3.81 
50-SMA 3.82 
52-W High 32 
52-W Low 1.8301 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.00/-4.84
Enterprise Value
9.63M
Balance Sheet
Book Value Per Share
1.52
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
839.36K
Operating Revenue Per Share
0.69
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 18:49 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.